Warm Autoimmune Hemolytic Anemia Market Summary

Warm Autoimmune Hemolytic Anemia (wAIHA) Insights and Trends

• In 2025, the wAIHA market across the 7MM was valued at approximately USD 600 million, reflecting a modest but growing market.
• In 2025, the total number of diagnosed prevalent cases of wAIHA across the 7MM was estimated at approximately 88,000.
• The United States accounted for the largest share of diagnosed prevalent wAIHA cases in the 7MM, contributing around half (~50%) of the total disease burden.
• Currently, there are no marketed therapies specifically approved for wAIHA, highlighting a significant unmet medical need and creating opportunities for emerging targeted treatments to reshape the future therapeutic landscape.
• In February 2026, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of IMAAVY (nipocalimab-aahu) as a potential first treatment for patients with wAIHA.
• Emerging therapies currently under clinical development for wAIHA include IMAAVY (nipocalimab, FcRn inhibitor), WAYRILZ (rilzabrutinib, BTK inhibitor), ianalumab (anti-BAFF-R), povetacicept (APRIL/BAFF dual antagonist), and tafasitamab (anti-CD19). These agents aim to improve disease management by targeting pathogenic B cells and autoantibody-mediated pathways.

Warm Autoimmune Hemolytic Anemia (wAIHA) Market size and forecast

• 2025 wAIHA Market Size: USD 600 million
• 2036 Projected wAIHA Market Size: USD 2.4 billion
• wAIHA Growth Rate (2026–2036): 14.4% CAGR

DelveInsight's ‘Warm Autoimmune Hemolytic Anemia (wAIHA) – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the wAIHA, historical and forecasted epidemiology, as well as the wAIHA market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The wAIHA market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, wAIHA patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in wAIHA and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Warm Autoimmune Hemolytic Anemia (wAIHA) Understanding and Treatment Algorithm

Warm Autoimmune Hemolytic Anemia (wAIHA) Overview and Diagnosis

wAIHA is an acquired autoimmune disorder in which IgG autoantibodies bind to red blood cells at body temperature. These antibody-coated erythrocytes are primarily destroyed by splenic macrophages, causing extravascular hemolysis. The resulting premature red cell destruction leads to anemia, jaundice, and often splenomegaly, reflecting ongoing immune-mediated hemolysis.

Diagnosis of wAIHA requires clinical and laboratory evidence of hemolysis. Patients typically present with anemia, jaundice, or dark urine. Laboratory findings include low hemoglobin, elevated LDH and indirect bilirubin, low haptoglobin, and reticulocytosis. Peripheral smear often shows spherocytes. Confirmation is based on a positive direct antiglobulin test (DAT) demonstrating IgG ± C3d. Evaluation for secondary causes, including autoimmune or lymphoproliferative disorders, is essential.

Further details are provided in the report.

Current Warm Autoimmune Hemolytic Anemia (wAIHA) Treatment Landscape

Treatment of wAIHA currently relies on off-label immunosuppressive therapies such as corticosteroids, rituximab, and supportive care including blood transfusions, highlighting a significant unmet need for disease-specific treatments. Emerging targeted therapies, including FcRn inhibitors, BTK inhibitors, aim to address the underlying autoantibody-driven mechanisms. Despite challenges such as heterogeneous disease presentation and small patient populations, ongoing clinical development and potential regulatory approvals are expected to drive growth in the wAIHA therapeutic market through 2036.

Further details related to country-based variations are provided in the report.

Warm Autoimmune Hemolytic Anemia (wAIHA) Unmet Needs

The section “unmet needs of wAIHA” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

• Lack of Approved, Disease-specific Therapies Across the 7MM
• Heavy Reliance on Corticosteroids and Off-label Treatments With Significant Safety/Tolerability Limits
• High Relapse Rates and a Lack of Consistently Durable Remission
• Heterogeneous Disease Biology Without Predictive Biomarkers

and others…..

Note: Comprehensive unmet needs insights in wAIHA and their strategic implications are provided in the full report.

Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology

Key Findings from Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiological Analysis and Forecast

• In 2025, the total number of diagnosed prevalent cases of AIHA across the 7MM was estimated at approximately 120,000.
• In the United States, primary wAIHA accounted for around 20,500 diagnosed prevalent cases in 2025, while secondary wAIHA comprised approximately 22,200 cases.
• In 2025, females accounted for about 60% of diagnosed prevalent wAIHA cases across EU4 and the UK, while males represented around 40%.
• In 2025, across EU4 and the UK, the ≥65 age group accounted for around 55% of wAIHA cases, followed by the 45–64 age group at approximately 25%.
• In 2025, in Japan, severe wAIHA accounted for around 420 cases, while non-severe cases were estimated at approximately 600.

Warm Autoimmune Hemolytic Anemia (wAIHA) Drug Analysis & Competitive Landscape

The wAIHA drug chapter provides a detailed, market-focused review of current treatment options and the emerging pipeline across Phase I–III clinical trials. It covers key aspects such as mechanism of action, clinical trial data, regulatory updates, patents, collaborations, strategic partnerships, and upcoming catalysts for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into wAIHA treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the wAIHA therapeutics market.

Warm Autoimmune Hemolytic Anemia (wAIHA) Pipeline Analysis

IMAAVY (nipocalimab): Johnson & Johnson

Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor (FcRn), inhibiting IgG recycling and reducing circulating pathogenic IgG antibodies. By lowering autoantibody levels, it has potential therapeutic benefits in IgG-mediated conditions such as warm autoimmune hemolytic anemia (wAIHA), where autoantibodies drive red blood cell destruction. Nipocalimab is currently being evaluated in a Phase II/III clinical trial for the treatment of warm wAIHA. In February 2026, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of IMAAVY as a treatment for patients with wAIHA.

Warm Autoimmune Hemolytic Anemia (wAIHA) Key Players, Market Leaders and Emerging Companies

• Johnson & Johnson
• Sanofi
• Novartis
• Vertex Pharma
• Incyte Corporation
• and others

Warm Autoimmune Hemolytic Anemia (wAIHA) Drug Updates

• In February 2026, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the US FDA seeking approval of IMAAVY (nipocalimab-aahu) as a treatment for patients with wAIHA.
• According to the Novartis 2026 investor presentation, the Phase III data readout for ianalumab in wAIHA is anticipated in second half of 2026.
• In February 2026, the US FDA granted BTD to WAYRILZ (rilzabrutinib) for the treatment of patients with wAIHA. Additionally, Japan’s Ministry of Health, Labour and Welfare granted rilzabrutinib ODD for the same indication.

Warm Autoimmune Hemolytic Anemia (wAIHA) Market Outlook

The wAIHA market is entering a phase of transformation after decades of relying on broad immunosuppression with corticosteroids, rituximab, and other nonspecific immunosuppressants. These treatments often provide temporary disease control but are associated with frequent relapse, steroid dependence, and cumulative toxicity. Despite the significant disease burden, there are currently no therapies specifically approved for wAIHA in most major markets, highlighting a substantial unmet medical need.

• The emerging pipeline is shifting the field toward mechanism-driven immune modulation, with late-stage candidates targeting key pathways involved in IgG-mediated hemolysis. Notable programs include IMAAVY (nipocalimab) from Johnson & Johnson, WAYRILZ (rilzabrutinib) from Sanofi, and ianalumab from Novartis.
• Overall, the emergence of targeted therapies and increasing recognition of disease burden are expected to drive steady growth in the 7MM wAIHA market from 2022–2036, with significant commercial potential for emerging pipeline treatments.
• In 2025, the United States accounted for the largest share of the wAIHA market within the 7MM, representing nearly 60% of the total market value.
• In 2036, among all the therapies for wAIHA, the highest revenue is estimated to be generated by IMAAVY, in the United States.
• The entry of late-stage candidates such as IMAAVY, Ianalumab, and WAYRILZ is expected to intensify competition in the second half of the forecast period.

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in Warm Autoimmune Hemolytic Anemia (wAIHA) (2022–2036 Forecast)

The wAIHA market comprises monoclonal antibodies, small-molecule inhibitors, and conventional immunosuppressive therapies, each targeting different components of immune-mediated hemolysis.

Monoclonal antibodies: Emerging biologics such as IMAAVY and ianalumab (aim to reduce pathogenic IgG levels and disrupt B-cell survival pathways, representing mechanism-driven approaches targeting the underlying immunopathology of wAIHA.

Small molecules: Oral agents such as WAYRILZ (rilzabrutinib), a BTK inhibitor in late-stage development, target B-cell receptor signaling and downstream immune activation, offering convenient administration and potential steroid-sparing benefits.

Conventional immunosuppressive therapies: Current management relies on corticosteroids, rituximab, and other immunosuppressants to control hemolysis, although these treatments are associated with relapse and cumulative toxicity.

Monoclonal antibodies and small molecules define the evolving innovation landscape, with biologics introducing targeted immune modulation and small molecules expanding the pipeline with convenient oral options.

Warm Autoimmune Hemolytic Anemia (wAIHA) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the wAIHA drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in wAIHA is expected to show clear differentiation between targeted biologics and oral immune modulators. Emerging biologics such as nipocalimab and ianalumab are anticipated to demonstrate relatively rapid uptake following approval, driven by their mechanism-based targeting of key immune pathways, significant unmet clinical need, and the absence of therapies specifically approved for wAIHA in most major markets. Their adoption may also benefit from physician familiarity with biologic therapies in other autoimmune conditions and the potential to reduce steroid dependence.

Drugs such as IMAAVY are projected to exhibit a medium-fast growth, achieving peak sales within approximately seven years, supported by differentiated efficacy and targeted positioning within the treatment paradigm.

Detailed insights of emerging therapies' drug uptake is included in the report

NOTE: Further Details are provided in the final report….

Warm Autoimmune Hemolytic Anemia (wAIHA) therapies Price Scenario & Trends

Pricing and analogue assessment of wAIHA therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most approproiate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Pricing of wAIHA Treatment

Rituximab is widely used in the management of wAIHA with multiple dosing regimens reflecting real-world clinical practice, including the lymphoma-based regimen (375 mg/m² weekly ×4), the autoimmune-style regimen (1,000 mg on Days 1 and 15), and a low-dose fixed regimen (100 mg weekly ×4). Based on a utilization-weighted costing approach, the estimated annual treatment cost is approximately USD 20,672 per patient in the US, compared with USD 13,437 in EU4 and the UK and USD 4,134 in Japan, reflecting regional pricing differences and treatment practices.

Industry Experts and Physician Views for Warm Autoimmune Hemolytic Anemia (wAIHA)

To keep up with wAIHA market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the wAIHA emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in wAIHA, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the Massachusetts General Hospital, University of Milan, University of Manchester, etc. were contacted.Their opinion helps understand and validate current and emerging wAIHA therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in wAIHA.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of wAIHA, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of wAIHA, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the wAIHA market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM wAIHA market.

Report Insights

• Warm Autoimmune Hemolytic Anemia (wAIHA) Patient population forecast
• Warm Autoimmune Hemolytic Anemia (wAIHA) therapeutics market size
• Warm Autoimmune Hemolytic Anemia (wAIHA) pipeline analysis
• Warm Autoimmune Hemolytic Anemia (wAIHA) market size and trends
• Warm Autoimmune Hemolytic Anemia (wAIHA) market opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) bottom‑up forecasting
• Artificial Intelligence (AI)-enabled market research report
• 11-year forecast
• Warm Autoimmune Hemolytic Anemia (wAIHA) market outlook
• Patient Burden trends (by geography)
• Warm Autoimmune Hemolytic Anemia (wAIHA) Treatment addressable Market (TAM)
• Warm Autoimmune Hemolytic Anemia (wAIHA) Competitve Landscape
• Warm Autoimmune Hemolytic Anemia (wAIHA) major companies Insights
• Warm Autoimmune Hemolytic Anemia (wAIHA) Price trends and analogue assessment
• Warm Autoimmune Hemolytic Anemia (wAIHA) Therapies Drug Adoption/Uptake
• Warm Autoimmune Hemolytic Anemia (wAIHA) Therapies Peak Patient Share analysis

Report Assessment

• Warm Autoimmune Hemolytic Anemia (wAIHA) Current treatment practices
• Warm Autoimmune Hemolytic Anemia (wAIHA) Unmet needs
• Warm Autoimmune Hemolytic Anemia (wAIHA) Clinical development Analysis
• Warm Autoimmune Hemolytic Anemia (wAIHA) emerging drugs product profiles
• Warm Autoimmune Hemolytic Anemia (wAIHA) Market attractiveness
• Warm Autoimmune Hemolytic Anemia (wAIHA) Qualitative analysis (SWOT and conjoint analysis)

FAQs

Market Insights

• What was the wAIHA market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of wAIHA?
• What are the disease risks, burdens, and unmet needs of wAIHA? What will be the growth opportunities across the 7MM concerning the patient population with wAIHA?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of wAIHA? What are the current guidelines for treating wAIHA in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the wAIHA market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.